| Description | Baloxavir marboxil (S-033188) is a novel cap-dependent endonuclease inhibitor for the treatment of influenza A and B virus infections. |
| Synonyms | S-033188 |
| molecular weight | 571.55 |
| Molecular formula | C27H23F2N3O7S |
| CAS | 1985606-14-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 60 mg/mL (104.98 mM) |
| References | 1. Koszalka P , Tilmanis D , Hurt A C . Influenza antivirals currently in late-phase clinical trial[J]. Influenza and Other Respiratory Viruses, 2017, 11(3):240-246. |
| Citations | 1. Liu K, Li L, Liu Y, et al.Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: biological evaluation of in vitro and in vivo.Antiviral Research.2024: 105890. |